Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Inclusion Criteria:

1. No evidence of extrahepatic disease
2. Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
3. Child Pugh score class A
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
5. Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria
6. Adequate organ and marrow function

Exclusion Criteria:

1. History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia
2. History of hepatic encephalopathy
3. Major portal vein thrombosis visible on baseline imaging
4. Uncontrolled arterial hypertension
5. Co-infection with HBV and HDV